These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension.
    Author: Sullivan PA, Dineen M, Cervenka J, O'Connor DT.
    Journal: Am J Hypertens; 1988 Jul; 1(3 Pt 3):280S-283S. PubMed ID: 2970855.
    Abstract:
    Fosenopril, a new angiotensin-converting enzyme (ACE) inhibitor, is a prodrug that is converted to its active diacid metabolite after intestinal absorption. Its excretion is equally divided between hepatic and renal routes. This study details the efficacy of fosenopril at rest and during exercise on blood pressure, plasma potassium, plasma renin activity, and plasma aldosterone in 11 hypertensive males, mean age 55 years. Individual subjects underwent an identical exercise protocol (bicycle ergometry) on placebo and on active treatment. Supine mean blood pressure fell from 116 to 100 mm Hg, P less than 0.005, and at 9 minutes of exercise mean blood pressure fell from 137 to 125 mm Hg, P less than 0.01 on fosenopril. Plasma potassium fell slightly at rest from 4.27 to 3.96 mmol/L and during exercise from 5.23 to 4.93 mmol/L, both P less than 0.025. Plasma renin activity (ng/mL/hr) rose on fosenopril, at rest 0.94 to 4.72, and during exercise 2.06 to 10.39, both P less than 0.005. Aldosterone changes on treatment were marginal and nonsignificant. The compound was well tolerated and free of subjective and routine laboratory side effects. Its antihypertensive action is broadly similar to the other ACE inhibitors currently available.
    [Abstract] [Full Text] [Related] [New Search]